Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Surrozen, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/13/2023 8-K Quarterly results
08/09/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Surrozen Provides Second Quarter 2023 Financial Results SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate prioritization efforts expected to provide cash runway extension into 2025 SOUTH SAN FRANCISCO, Calif., August 9, 2023 -- Surrozen, Inc. , a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided second quarter 2023 financial results and corporate and pipeline updates. “During the second quarter of 2023, we made important progress in the Phase 1a clinical trials f..."
07/19/2023 8-K Quarterly results
07/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/10/2023 8-K Quarterly results
Docs: "SURROZEN, INC. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 8,086 $ 9,371 General and administrative 5,299 5,122 Restructuring 1,207 — Total operating expenses 14,592 14,493 Loss from operations Interest income 547 49 Other income , net 6,497 Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 29,971 34,863 SURROZEN, INC. Condensed Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 27,809 $ 24,690 Accounts receivable 1,978 1,978 Short-term marketable securities 33,937 51,148 Prepaid expen..."
04/06/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/31/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/31/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/31/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/23/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/23/2023 8-K Other Events  Interactive Data
03/22/2023 8-K Quarterly results
Docs: "SURROZEN, INC. Consolidated Statements of Operations and Comprehensive Loss Year Ended December 31, 2022 2021 Collaboration and license revenue $ 12,500 $ — Operating expenses: Research and development 37,013 40,177 General and administrative 19,826 14,214 Total operating expenses 56,839 54,391 Loss from operations Interest income 781 72 Other income , net 7,554 Net loss $ $ Net loss per share attributable to common stockholders, basic and diluted $ $ Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 34,722 24,689 SURROZEN, INC. Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 24,690 $ 33,091 Accounts receivable 1,978 — Short-term marketable securities 51,148 68,760 Prepa..."
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 2.3% stake in Surrozen, Inc.
02/13/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/02/2023 SC 13G BML Investment Partners, L.P. reports a 5.6% stake in Surrozen, Inc./DE
02/02/2023 SC 13G/A REGENTS OF THE UNIVERSITY OF CALIFORNIA reports a 5.9% stake in Surrozen Inc.
01/05/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/05/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/05/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
12/21/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/20/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/15/2022 SC 13D/A Consonance Capital Management LP reports a 0% stake in Surrozen, Inc.
12/15/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/15/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/15/2022 8-K Other Events  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy